Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Johnson & Johnson Dips On Q4 Earnings
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.
US FDA approves new nasal spray for depression treatment
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for Spravato (esketamine) as a monotherapy for adults living with treatment-resistant depression (TRD).
Bears officially announce Ben Johnson
Brad Biggs: Guided by self-awareness, Ben Johnson is finally prepared for his role as head coach of the Bears
Ben Johnson launched into his virtual interview with the Chicago Bears leaving no question as to his intentions. “I want this job,” Johnson said, Chairman George McCaskey recalled. The feeling was mutual and the Bears agreed to terms with Johnson on Monday.
Lions lose Aaron Glenn, Ben Johnson to head coaching jobs: Identifying internal replacements for coordinators
Now, the Lions are also starting over at both the offensive coordinator and defensive coordinator positions on their coaching staff, with OC Ben Johnson being hired to be the next head coach of the Chicago Bears and DC Aaron Glenn being hired to be the next head coach of the New York Jets.
Chicago Bears appoint Johnson as new head coach
The Chicago Bears have appointed Ben Johnson as their new head coach. Johnson, 38, has been with the Detroit Lions since 2019 and spent the past three seasons as their offensive co-ordinator. He succeeds Matt Eberflus,
18h
Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
MassDevice
19h
Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
20h
on MSN
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness
Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...
1d
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
MarketBeat on MSN
5d
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...
6d
on MSN
Mike Johnson has a new headache in the narrowly divided House: From the Politics Desk
Johnson sent shockwaves around Capitol Hill when he decided to oust Rep. Mike Turner, R-Ohio — a staunch NATO supporter who ...
5d
Hold Rating for Johnson & Johnson Amid Modest Growth Outlook and Legal Uncertainties
In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...
6d
Johnson Installs Crawford on Intelligence Panel, Pulling It Closer to Trump
The speaker replaced a Republican who had criticized the president-elect and broken with him on key issues, and who had drawn ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback